Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Transforming Growth Factor Beta 1 (TGFB1) - Transforming growth factor beta 1 (TGF-β1) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB1 gene. It plays an important role in bone remodeling as it is a potent stimulator of osteoblastic bone formation, causing chemotaxis, proliferation, and differentiation in committed osteoblasts. It promotes either T-helper 17 cells (Th17) or regulatory T-cells (Treg) lineage differentiation in a concentration-dependent manner. It leads to FOXP3-mediated suppression of RORC and down-regulation of IL-17 expression at high concentration. It leads to expression of the IL-17 and IL-23 receptors favoring differentiation to Th17 cells at low concentration.
Transforming Growth Factor Beta 1 (TGFB1) pipeline Target constitutes close to 41 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 10, 1, 14 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 6 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Musculoskeletal Disorders, Ophthalmology, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Genetic Disorders, Infectious Disease, Cardiovascular, Central Nervous System, Dermatology, Hematological Disorders and Male Health which include indications Solid Tumor, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Non-Small Cell Lung Cancer, Colorectal Cancer, Kidney Fibrosis, Liver Fibrosis, Myelofibrosis, Bile Duct Cancer (Cholangiocarcinoma), Breast Cancer, Diabetic Nephropathy, Fibrosis, Liver Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Squamous Cell Carcinoma, Bladder Cancer, Corneal Dystrophy, Coronavirus Disease 2019 (COVID-19), Glioblastoma Multiforme (GBM), Melanoma, Metastatic Liver Cancer, Non-Alcoholic Steatohepatitis (NASH), Osteoarthritis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Sclerosing Cholangitis, Renal Cell Carcinoma, Systemic Sclerosis (Scleroderma), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Triple-Negative Breast Cancer (TNBC), Unspecified Cancer, Age Related Macular Degeneration, Alport Syndrome, Anemia, Basal Cell Carcinoma (Basal Cell Epithelioma), Benign Prostatic Hyperplasia, Bone Disorders, Cholangitis, Choroidal Neovascularization, Colitis, Colon Cancer, Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Glaucoma, Gynecological Cancer, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hyperalgesia, Hypertrophic Scars, Inflammation, Interstitial Lung Fibrosis, Keloids, Lung Adenocarcinoma, Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Nonmelanomatous Skin Cancer, Open-Angle Glaucoma, Osteogenesis Imperfecta, Pancreatitis Pain, Proliferative Vitreoretinopathy (PVR), Pulmonary Hypertension and Transitional Cell Cancer (Urothelial Cell Cancer).
The latest report Transforming Growth Factor Beta 1 (TGFB1) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update, outlays comprehensive information on the Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transforming Growth Factor Beta 1 (TGFB1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
AiViva BioPharma Inc
AskGene Pharma Inc
Avellino Lab USA Inc
Bristol-Myers Squibb Co
Certa Therapeutics Pty Ltd
Chengdu Huitai Biomedicine Co Ltd
Chugai Pharmaceutical Co Ltd
Ensol Biosciences Inc
Guangzhou Nanxin Pharmaceutical Co Ltd
Isarna Therapeutics GmbH
Johnson & Johnson
Lepu Biopharma Co Ltd
Nanjing Shenghe Pharmaceutical Co Ltd
Phio Pharmaceuticals Corp
Scholar Rock Inc
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook